Skip to main navigationSkip to main content
The University of Southampton
We're launching a new website soon and would love your feedback. See the new design

Professor James Raftery MA, PhD

Professor of Health Technology Assessment, Chair NETSCC, Director Wessex Institute

Professor James Raftery's photo
Related links

James is Professor of Health Technology Assessment at the University of Southampton and formerly chair of the NIHR Evaluation Trials and Studies Cooodinating Centre (NETSCC). He has led several research projects including most recently an update of the literature on assessing the impact of the HTA programme, and a report on “metadata" on the performance, conduct and results of clinical trials.

He is an active health economist, part of a group providing health economics input mainly to clinical trials. Research themes include the costs and benefits of clinical trials, overdiagnosis/overtreatment and the political economy of healthcare. He has written widely on health economic matters particularly relating to NICE, including a NICE blog on the BMJ website.


BA Economics and Philsophy, 1972 Southampton University
MA Economics of Education and Science, UCD, 1974
PhD LSE 1993

Research interests

Recent publications includes:

  1. Treatment success in pragmatic randomized controlled trials: a review of trials funded by the UK Health Technology Assessment programme. L.Dent, J. Raftery. Trials 2011)
  2. "Flogging dead horses": evaluating when have clinical trials achieved sufficiency and stability? A case study in cardiac rehabilitation. L Dent, J. Raftery .Trials 2011)
  3. The CHD challenge: comparing four cost-effectiveness models. D. Turner, J Raftery, Jan;14(1):53-60. ... Turner D, Raftery J, Cooper K, Fairbank E, Palmer S, Ward S, Ara R. Accepted Value in Health. 2011.
  4. Multiple Sclerosis risk sharing scheme: a costly failure. JR. BMJ, 340. 3/6/2010
  5. Should NICE’s threshold range for cost per QALY be raised? No. James Raftery. BMJ 2009;338:b185, doi: 10.1136/bmj.b185 (Published 26 January 2009).
  6. NICE and the challenge of cancer drugs. James Raftery BMJ 2009;338:b67, doi: 10.1136/bmj.b67 (Published 13 January 2009).
  7. Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study. J Raftery, J Bryant, J Powell, C Kerr, S Hawker. Health Technology Assessment 2008, Volume 12, no .10.)
  8. The Birmingham rehabilitation uptake maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation. K Jolly, G Y H Lip, R S Taylor, J Raftery, J Mant, D Lane, S Greenfield, and A Stevens. Heart 2009; 95: 36-42. doi:10.1136/hrt.2007.127209. (Heart 
  9. See monograph report The Birmingham Rehabilitation Uptake Maximisation Study (BRUM). Home-based compared with hospital-based cardiac rehabilitation in a multi-ethnic population: cost-effectiveness and patient adherence. K Jolly,1* R Taylor,2 GYH Lip,3 S Greenfield,4 J Raftery,5 J Mant,4 D Lane,3 M Jones,4 KW Lee6 and A Stevens1 HTA Health Technology Assessment 2007; Vol 11: number 35.
  10. Paying clinicians to join clinical trials: a review of guidelines and interview study of trialists James Raftery, Christine Kerr1, Sheila Hawker1 and John PowellTrials 2009, 10:15 doi:10.1186/1745-6215-10-15.
  11. Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study. J Raftery, J Bryant, J Powell, C Kerr, S Hawker. Health Technology Assessment 2008, Volume 12, no .10.
  12. Aspirin in Alzheimer’s disease (AD200): a randomised open label trial. AD2000 Collaborative Group. Neurology Lancet. 7 January 2008. (see below for JR role in AD2000 Collaborative).
  13. Paying for cost pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Raftery J. Medical Journal of Australia. 188, 1. 26-28. 7 January. 2008
  14. An assessment of the impact of the NHS health technology assessment programme. S Hanney, M Buxton, C Green, D Coulson, J Raftery. Health Technology Assessment 2007. 11,53.
  15. Assessing the impact of England's National Health Service R&D Health Technology Assessment program using the “payback” approach. James Raftery, Stephen Hanney, Colin Green and Martin Buxton, International Journal of Technology Assessment in Health Care (2009), 25: 1-5. DOI: 10.1017/S0266462309090011.
  16. Ranibizumab (lucentis) versus bevacizumab (avastin): modelling cost effectiveness James Raftery, Jeremy Jones, Andew Clegg, and Andrew Lotery. British Journal of Ophthalmology. September 2007 91:1244-1246.
  17. A brief pan management program compared with physical therapy for low back pain: results from an economic analysis alongside a randomized clinical trial. DG Whitehurst, M Lewis, GL Yao, S Bryan, JP Raftery, R Mullis EM Hay. Arthritis and Rheumatism. 57, 3, 2007. 466-473.
  18. DNA may not mean ‘did not participate’: a qualitative study of reasons for non-adherence tat home and centre based cardiac rehabilitation Jones M, Jolly K, Raftery J, Lip GYH, Greeenfield S. on behalf of the BRUM Steering Group. Family Practice 2007 24: 343-357.
  19. The Birmingham Rehabilitation Uptake Maximisation Study (BRUM). Home-based compared to hospital-based cardiac rehabilitation in a multi-ethnic population: cost effectiveness and patient adherence. Jolly K, Taylor R, Lip GYH, Greenfield S, Raftery J, Mant J, Land D, Jones M, Lee KW, Stevens A. Health Technology Assessment 2007, vol 13, No 35. 
  20. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trail. Fitzmaurice DA, Hobbs FDR, Jowett S, Mant J, Murray ET, Holder R, Raftery JP, Bryan S, Davies M, Lip GYH, Allan TF.BMJ, Aug 2007; 335: 383.
  21. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Mant J, Hobbs R, Fletcher K, Mant J, Fletcher K, et al; BAFTA investigators; Midland Research Practices Network (MidReC). Lancet 2007;370:493-503. (JR was member of BAFTA investigators.] 
  22. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. J Wilson, GL Yao, J Raftery, J Bohlius, S Brunskill, J Sandercock, S Bayliss,P Moss, S Stanworth and C Hyde. Health Technology Assessment 2007 Volume 11, 13
  23. Economic Evaluations of Calcineurin Inhibitors in Renal Transplantation: A Literature Review. Miners AH, Yao G, Raftery J, Taylor RS.Pharmacoeconomics. 2007;25:935-947.


Primary Care, Population Sciences and Medical Education

Research project(s)

BREATHE (Breathing Retraining for Asthma Trial of Home Exercise)

Although effective medicinal treatment exists for asthma, many people continue to have distressing symptoms and impaired quality of life. People with asthma have expressed interest in non-drug asthma treatments, particularly in breathing exercises. Several recent studies have shown benefits from a short course of breathing exercises taught by a respiratory physiotherapist for people with asthma who remained symptomatic despite usual treatment. We believe that many NHS patients could potentially benefit from these exercises, but unfortunately, there is currently not enough access to suitable trained physiotherapists able to provide such a service. We propose to provide the same breathing training programme that we have previously shown to be effective when taught 'face-to-face' by a physiotherapist in the form of a DVD, or internet download. Patients will use this in their own home at times convenient to them, in addition to their standard treatment (e.g. with inhalers). We will find out whether this type of instruction is better than the 'usual care' that is currently provided, and whether it is as good as the 'face to face' physiotherapist instruction (which is more expensive and less convenient for patients).


The DIPSS (Integrating Digital Interventions into Patient Self-Management Support) project has received funding of £2 million from the NIHR to examine patient digital self-management with healthcare professional support in primary care. Our aim is to develop digital behaviour change interventions for asthma and hypertension self-management, which will be examined in feasibility studies and full RCT (hypertension only). Issues surrounding the feasibility, acceptability, effectiveness and cost-effectiveness of digital intervention delivery will be explored with patients and healthcare professionals for each condition.


A randomised control trial, economic and qualitative evaluation to examine the effectiveness of an out-of-court community-based Gateway intervention programme aimed at improving health and well-being for young adult offenders; victim satisfaction and reducing recidivism

Antenatal Couples’ Counselling in Uganda (ACCU)


A primary care trial of a website based infection control intervention to modify influenza-like illness and respiratory infection transmission.

Provides health economics inputs on request to research bids from Southampton University. Currently providing health economics input to some 20 funded research projects.

NETSCC runs 5 UK wide research programmes for the National Insitute of Health Research (NIHR) . NETSCC also represents NIHR internationally.

Sort via:TypeorYear




  • Health economics
  • Overtreatment
  • Clinical trials
  • NICE
  • Use of routine data in HTA
Professor James Raftery
Faculty of Medicine, Room AB215, Mailpoint 801, South Academic Block, University Hospital Southampton, Tremona Road, Southampton, SO16 6YD
Share this profile Share this on Facebook Share this on Twitter Share this on Weibo
Privacy Settings